<div>
  <ul>
    <li>
      <p>
        Massachusetts-based AI cell therapy company Cellino Biotech has raised USD 80 million in a Series A funding round led by Leaps by Bayer (the impact investment arm of Bayer AG) and Humboldt Fund. Among others, existing investor Khosla Ventures and new investor Felicis Ventures also participated in the round.&nbsp;
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        The proceeds will be directed toward advancing its AI-based platform with improved machine learning and hardware capabilities to offer both autologous (using patient&rsquo;s own cells) and allogeneic (using donor cells) therapies. The company also plans to build a good manufacturing practices (GMP) standard facility to assist in clinical trials.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20220125005433/en/Leaps-by-Bayer-Leads-80M-Series-A-Financing-for-Cellino-Biotech-to-Autonomize-Stem-Cell-Therapy-Manufacturing">
      Business Wire
    </a>
  </p>
  <p>
    <a href="https://techcrunch.com/2022/01/25/startup-battlefield-winner-cellino-grabs-80m-series-a/">
      Tech Crunch
    </a>
  </p>
  <p>
    <a href="https://www.fiercepharma.com/manufacturing/bayer-leads-80-million-series-a-investment-betting-cellino-biotech-s-cell-therapy">
      Fierce Pharma
    </a>
  </p>
</div>


All Updates

Cellino Biotech raises USD 80 million in Series A